<DOC>
	<DOCNO>NCT01978652</DOCNO>
	<brief_summary>The primary objective study characterise pharmacokinetics ( PK ) BIIB017 ( Peginterferon Beta-1a ) administer single 125 μg subcutaneous ( SC ) dose Japanese Caucasian adult healthy participant . The secondary Objective ass safety tolerability single 125 μg subcutaneous ( SC ) dose BIIB017 Japanese Caucasian adult healthy participant .</brief_summary>
	<brief_title>Pharmacokinetic Study Peginterferon Beta-1a Japanese Caucasian Adult Healthy Participants .</brief_title>
	<detailed_description />
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Key Must BMI 19 29 kg/m2 , inclusive , minimum body weight 45.0 kg Screening Baseline . Japanese subject must bear Japan parent grandparent Japanese origin . Additionally , Japanese subject live outside Japan le 5 year maintain similar diet since leave Japan ( verified questionnaire Screening ) . Subjects childbearing potential must practice effective contraception study willing able continue contraception 90 day last dose study treatment . Non smoker willing abstain use tobacco tobaccocontaining product 24 hour prior clinic admission InClinic Period smoke 10 cigarette ( equivalent ) per day throughout remainder study . Must willing refrain alcohol consumption 48 hour prior Day 1 InClinic Period limit intake alcohol 2 unit per day throughout remainder study . Key Known history , positive test result Screening human immunodeficiency virus ( HIV ) . Known history , positive test result hepatitis C virus ( test hepatitis C virus antibody [ HCV Ab ] ) hepatitis B virus ( test hepatitis B surface antigen [ HBsAg ] ) . Subjects history malignant disease , include solid tumour haematologic malignancy ( except basal cell squamous cell carcinoma skin completely excise consider cured subject cervical cancer stage 0 completely excise ) . History severe allergic anaphylactic reaction opinion Investigator . Known allergy interferon component BIIB017 . History suicidal ideation episode clinically significant depression ( determined Investigator ) within 3 month prior Day 1 . Any previous treatment prescription investigational pegylated drug . The prior use overthecounter pegylated product , include cosmetic , allow . Previous treatment interferon product . History hypersensitivity intolerance paracetamol , ibuprofen , naproxen , would preclude use least 1 study . NOTE : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>